FABP4 and acute respiratory failure: While its performance as a LRTI biomarker exceeds clinical biomarkers such as C-reactive protein12 or procalcitonin13, FABP4 alone likely does not achieve the accuracy necessary to enable confident clinical decisions regarding antimicrobial use in critically ill patients with acute respiratory failure.